Welcome to our dedicated page for Nautilus Biotechnology SEC filings (Ticker: NAUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Nautilus Biotechnology's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Nautilus Biotechnology's regulatory disclosures and financial reporting.
Nautilus Biotechnology, Inc. director Karen Akinsanya received a grant of stock options as part of her compensation. The award covers 45,000 options to buy common stock at an exercise price of $2.28 per share, expiring on June 18, 2036.
These options vest in equal monthly installments over 12 months following the grant date, as long as she continues as a qualifying “Service Provider” under the company’s 2021 Equity Incentive Plan. After this grant, she holds 45,000 stock options directly.
Nautilus Biotechnology director Matthew S. McIlwain received a grant of stock options for 45,000 shares of common stock. These options have an exercise price of $2.28 per share and expire on June 18, 2036. Following this grant, he holds options for 45,000 shares directly.
The options were awarded as compensation, not purchased in the open market, and vest over time. One-twelfth of the options vest each month after the grant date as long as he continues to serve as a qualifying service provider to the company.
Nautilus Biotechnology director Melissa B. Epperly received a grant of stock options covering 45,000 shares of common stock. The options have an exercise price of $2.28 per share and expire on June 18, 2036.
These options vest in equal monthly installments over 12 months, with one-twelfth of the grant vesting each month after the grant date, as long as she continues to serve as a “Service Provider” under the company’s 2021 Equity Incentive Plan. Following this grant, she holds 45,000 stock options directly.
Nautilus Biotechnology, Inc. reported the results of its 2026 annual stockholder meeting held on June 17, 2026. Of 127,078,855 common shares outstanding as of April 20, 2026, 85,002,191 were represented in person or by proxy, indicating strong participation.
Stockholders elected Class II directors Parag Mallick and Farzad Nazem, each to serve until the 2029 annual meeting. They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026.
In an advisory vote, stockholders approved the 2025 executive compensation program and expressed a preference to hold future advisory votes on executive pay every one year. The company plans to conduct annual Say on Pay votes until the next required frequency vote, scheduled no later than the 2032 annual meeting.
Andreessen Horowitz–affiliated funds filed an amended Schedule 13D for Nautilus Biotechnology to reflect recent share sales and updated holdings. AH Bio Fund II and Andreessen Horowitz LSV Fund II sold 4,615,974 and 384,026 Nautilus common shares, respectively, on June 2, 2026 in a single block trade at $2.35 per share.
After these transactions, Marc Andreessen and Benjamin Horowitz are each reported to beneficially own 12,653,917 shares, representing approximately 9.96% of Nautilus’s common stock based on 127,078,855 shares outstanding as of April 23, 2026, though EDGAR cover pages round this to 9.9%. The filing details their sole and shared voting and dispositive powers through various venture funds and general partner entities.
Nautilus Biotechnology, Inc. disclosed that investment funds affiliated with Andreessen Horowitz executed open-market sales of common stock. AH Bio Fund II, L.P. sold 4,615,974 shares of common stock at $2.35 per share, leaving 11,682,032 shares of common stock held indirectly. Andreessen Horowitz LSV Fund II, L.P. sold 384,026 shares of common stock at $2.35 per share, with 971,885 shares of common stock remaining indirectly held. The funds are controlled through general partners AH Equity Partners Bio II, L.L.C. and AH Equity Partners LSV II, L.L.C., whose managing members are Marc Andreessen and Ben Horowitz, and the reporting persons disclaim group status and beneficial ownership beyond any pecuniary interest.
Nautilus Biotechnology, Inc. is holding its 2026 annual stockholder meeting virtually on June 17, 2026 at 10:00 a.m. Pacific Time. Holders of common stock as of April 20, 2026, when 127,078,855 shares were outstanding, may attend and vote online using a 16‑digit control number.
Stockholders will vote on electing two Class II directors through 2029, ratifying PricewaterhouseCoopers LLP as auditor for 2026, approving 2025 executive compensation on an advisory basis, and choosing how often to hold future say‑on‑pay votes. The board recommends voting for all proposals and selecting “one year” for say‑on‑pay frequency.
Nautilus Biotechnology reported a Q1 2026 net loss of $14.7 million, an improvement from $16.6 million a year earlier, as it continues developing its Nautilus Voyager proteomics platform with no product revenue yet. Research and development expenses fell to $9.7 million and selling, general and administrative costs declined to $6.4 million, reflecting prior cost reductions.
The company held $95.9 million in cash, cash equivalents and short‑term investments and $143.4 million including long‑term investments as of March 31, 2026, and believes this will fund operations for at least the next twelve months while it advances its Early Access Program and phased commercial launch planned for 2026–2027.
Nautilus Biotechnology reported first quarter 2026 results, showing lower spending and a narrower loss as it advances its proteomics platform toward commercialization. Operating expenses were $16.1 million, down 14% from $18.8 million a year earlier, mainly from lower salaries, stock-based compensation, and facilities costs.
Net loss improved to $14.7 million for the quarter, compared with $16.6 million in the prior-year period, or $0.12 per share versus $0.13. Cash, cash equivalents, and investments totaled $143.4 million as of March 31, 2026, supporting ongoing development of the Voyager platform and the new Iterative Mapping Early Access Program.
During the quarter, Nautilus initiated its Iterative Mapping Early Access Program with Baylor College of Medicine, advanced Tau proteoform assay work with collaborators, and appointed a new Vice President of Global Sales to drive early customer expansion ahead of full commercial launch.